Ratiotx

Ratio Therapeutics is a discovery-stage biotechnology company focused on developing advanced radiotherapeutics for the treatment of metastatic cancers. Utilizing a suite of proprietary technologies licensed from Cornell University, the company aims to create best-in-class targeted radiopharmaceuticals. These innovative compounds feature a tunable structural motif that allows them to reversibly bind to albumin, enhancing their pharmacokinetics (PK), improving drug availability, tumor delivery, and tumor loading, while minimizing side effects commonly associated with other radiotherapies.

The company operates in the biotechnology and pharmaceutical markets, primarily serving cancer patients and collaborating with major pharmaceutical companies for clinical trials. Ratio Therapeutics employs a business model that includes research and development, intellectual property licensing, and strategic alliances. Revenue is generated through partnerships, licensing agreements, and potential future sales of approved therapies.

The team at Ratio Therapeutics comprises experienced scientists and researchers with strong expertise and long-standing relationships with key opinion leaders (KOLs) in the field. The company holds robust intellectual property positions across multiple platform technologies and has set a target for two Investigational New Drug (IND) filings in early 2022.

Keywords: radiotherapeutics, cancer treatment, pharmacokinetics, albumin binding, metastatic cancers, biotechnology, pharmaceutical, clinical trials, intellectual property, strategic alliances.